Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2024-01-01 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
AI Driven Drug Discovery Collaboration with Google Cloud 2 pages 192.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 2 January 2024 from PYC Therapeutics about a new collaboration with Google Cloud to pursue AI-driven drug discovery. It details the terms of the collaboration, funding, and intellectual property rights. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is a corporate announcement about a strategic partnership and project initiation rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is also not a regulatory filing or certification. Given the nature of the content, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2024-01-01 English
RP11 Clinical Trial Progressing To High Dose Cohort 3 pages 278.1KB
Regulatory Filings Classification · 95% confidence The document is an announcement from PYC Therapeutics regarding the progression to a high dose patient cohort in a clinical trial for a drug candidate VP-001. It discusses clinical trial phases, safety review committee approvals, dosing cohorts, and forward-looking statements. There is no financial data, regulatory filing, or detailed financial report content. The document is a corporate announcement about clinical trial progress and drug development status, typical of a Capital/Financing Update or general corporate update. However, since it focuses on clinical trial progress and drug development rather than fundraising or capital structure changes, it does not fit CAP. It is not a regulatory filing or legal proceeding. The best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories, given it is an ASX announcement about clinical trial progress and drug development status without financial results or management discussion.
2023-12-17 English
Notification of cessation of securities - PYC 4 pages 23.9KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation of securities, specifically options that have expired without exercise or conversion. It provides details about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement related to changes in the company's securities, not a financial report or detailed analysis. It fits the category of a regulatory announcement about securities cessation rather than a report or financial statement. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-30 English
Response to Price Query 5 pages 331.1KB
Regulatory Filings Classification · 95% confidence The document is a letter from PYC Therapeutics Limited responding to a price query from the Australian Securities Exchange (ASX). It addresses questions about recent trading activity, compliance with listing rules, and disclosure of information. The content is a regulatory response to a market price query, not a financial report, earnings release, or other types of filings. It is a compliance communication related to continuous disclosure obligations under listing rules. The document is not a report itself but a regulatory filing responding to ASX inquiries. Therefore, it fits best under Regulatory Filings (RNS). The document length (9261 characters) and detailed Q&A format support this classification rather than a brief announcement or a full report.
2023-11-29 English
2023 AGM Chairman's Address and CEO Presentation 9 pages 1.4MB
AGM Information Classification · 95% confidence The document contains a Chairman's Address and CEO Presentation specifically prepared for the 2023 Annual General Meeting (AGM) of PYC Therapeutics. It includes forward-looking statements, company overview, pipeline updates, and strategic objectives typically presented at an AGM. The text explicitly states these materials are to be presented at the AGM held on the same day. There is no indication that this is a full Annual Report or financial statements, nor is it a brief announcement or regulatory filing. The content is consistent with presentations and materials shared during an AGM event.
2023-11-23 English
Results of Annual General Meeting 2 pages 215.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled '2023 Results of Annual General Meeting' and details the outcomes of resolutions voted on at the AGM of PYC Therapeutics Limited held on 24 November 2023. It includes voting results, proxy information, and references to the Corporations Act and Listing Rule 3.13.2. The content is focused on announcing the results of shareholder votes at the AGM, not the AGM materials themselves or the full annual report. The document length is 4207 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2023-11-23 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.